National Comprehensive Cancer Network

About NCCN

Updated NCCN Guidelines for Patients® and New NCCN Quick Guide™ for Multiple Myeloma Now Available

Lacey Marlow, Associate Medical Writer, NCCN

The National Comprehensive Cancer Network® (NCCN®) has published an updated NCCN Guidelines for Patients®: Multiple Myeloma as well as the first NCCN Quick Guide™ for Multiple Myeloma. This NCCN Patient Guideline has been updated from Version 1.2014 to Version 1.2015 to reflect the most recent updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma.

The NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2015, includes important changes to recommended systemic therapy options and combinations in the treatment guide. Two new combination regimens have been added as options for additional treatment for relapse or progressive disease. One new option is the combination of carfilzomib, lenalidomide, and dexamethasone. The second new option is the combination of panobinostat, bortezomib, and dexamethasone. Panobinostat (Farydak) is the newest drug to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. It is indicated for patients who have received at least two prior treatments, including bortezomib (Velcade) and an immunotherapy drug.

The NCCN Quick Guide™ for Multiple Myeloma summarizes key points of the NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2015. Key points include myeloma assessment for treatment planning and recommended options for initial and subsequent treatment.

The NCCN Guidelines for Patients® and NCCN Quick Guide™ for Multiple Myeloma provide the same current and accurate cancer information on health care options that clinicians access in the NCCN Guidelines®. Digital versions of these patient resources are available to view and download free-of-charge on NCCN.org/patients.

NCCN currently offers NCCN Guidelines for Patients for the following: Breast Cancer: Stages 0-IV; Colon, Esophageal, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphoblastic Leukemia; Caring for Adolescents and Young Adults (AYA); Chronic Myelogenous Leukemia; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; and Soft Tissue Sarcoma. NCCN Quick Guide™ sheets are currently available for Esophageal Cancer, Prostate Cancer, Stage IV Breast Cancer, Lung Cancer Screening, and Multiple Myeloma.

NCCN is committed to developing a comprehensive patient library with support from the NCCN Foundation®